Global Non-alcoholic Steatohepatitis Biomarkers Market Size To Exceed USD 10.48 Billion by 2033: Market Insight Report

Global Non-alcoholic Steatohepatitis Biomarkers Market Size To Exceed USD 10.48 Billion by 2033

According to a research report published by Spherical Insights & Consulting, The Global Non-alcoholic Steatohepatitis Biomarkers Market Size is Expected to Grow from USD 1.29 Billion in 2023 to USD 10.48 Billion by 2033, at a CAGR of 23.30% during the forecast period 2023-2033.  

Browse 210 market data Tables and 45 Figures spread through 190 Pages and in-depth TOC on the Global Non-alcoholic Steatohepatitis Biomarkers Market Size, Share, and COVID-19 Impact Analysis, By Type (Serum Biomarkers and Hepatic Fibrosis Biomarkers), By End Use (Pharma & CRO Industry and Hospitals), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033

The global non-alcoholic steatohepatitis biomarkers market refers to the industry focused on developing and using biomarkers for the diagnosis, tracking, and management of non-alcoholic steatohepatitis (NASH), a liver condition. This market comprises technologies, treatments, and diagnostic equipment meant to enhance patient outcomes globally. Key driving factors for the growth of the non-alcoholic steatohepatitis biomarkers market include the increased rates of NASH and NAFLD worldwide, expanding awareness of liver health, improvements in biomarker research, an increase in customized medication, rising healthcare spending, and the demand for efficient treatment alternatives and early detection. However, regulatory obstacles, slow acceptance of new technologies in hospitals, high diagnostic costs, a lack of established biomarkers, and low awareness in emerging countries.

The serum biomarkers segment accounted for the largest revenue share in 2023 and is projected to grow at a significant CAGR during the forecast period.

On the basis of type, the global non-alcoholic steatohepatitis biomarkers market is divided into serum biomarkers and hepatic fibrosis biomarkers. Among these, the serum biomarkers segment accounted for the largest revenue share in 2023 and is projected to grow at a significant CAGR during the forecast period. The segment growth is attributed to increasing demand for non invasive diagnostic techniques because of their cost, convenience for ordinary clinical usage, and precision in monitoring liver fibrosis, inflammation, and disease progression.

The pharma & CRO industry segment accounted for the highest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period.

On the basis of end use, the global non-alcoholic steatohepatitis biomarkers market is divided into pharma & CRO industry and hospitals. Among these, the pharma & CRO industry segment accounted for the highest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period. The segment growth is driven by a growing emphasis on NASH medication development, a rise in clinical trials, and the requirement for dependable biomarkers to efficiently monitor the development of the disease and the effectiveness of treatment.

North America is anticipated to hold the largest share of the global non-alcoholic steatohepatitis biomarkers market over the predicted timeframe.

North America is anticipated to hold the largest share of the global non-alcoholic steatohepatitis biomarkers market over the predicted timeframe. The regional market growth can be attributed to diseases of the liver being widely recognized, diagnosis rates being high, and the medical system being strong. The industry is a leader in market expansion due to the early adoption of innovative diagnostic technologies and the regular introduction of novel biomarkers, which enable early identification, accurate monitoring, and successful treatment.

Asia Pacific is expected to grow at the fastest CAGR in the global non-alcoholic steatohepatitis biomarkers market during the forecast period. The regional market growth is driven by increasing demand for noninvasive diagnostics, growing spending on research and development by biotech companies, and expanding healthcare infrastructure. 

Company Profiling

Major vendors in the global non-alcoholic steatohepatitis biomarkers market are GENFIT, Prometheus Laboratories, Siemens Healthineers AG, BioPredictive, Quest Diagnostics, AstraZeneca, Exalenz Bioscience Ltd (meridian bioscience), Labcorp, Pfizer Inc., Bristol-Myers Squibb Company, and Others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In November 2024, Novo Nordisk announced that its weight-loss drug, semaglutide (marketed as Wegovy), met the primary endpoint in a late-stage trial for metabolic dysfunction-associated steatohepatitis (MASH), showing significant improvements in liver scarring without worsening the condition.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global non-alcoholic steatohepatitis biomarkers market based on the below-mentioned segments: 

Global Non-alcoholic Steatohepatitis Biomarkers Market, By Type

• Serum Biomarkers
• Hepatic Fibrosis Biomarkers

Global Non-alcoholic Steatohepatitis Biomarkers Market, By End Use

• Pharma & CRO Industry
• Hospitals

Global Non-alcoholic Steatohepatitis Biomarkers Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa